Sugi Predict

Sugi Predict / Compounds / SCHEMBL1246770

SCHEMBL1246770

SCHEMBL1246770

COC(=O)c1ccc(Cl)nc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.62
▸ NPC1 O15118 2/20 0.62
▸ RAB9A P51151 2/20 0.62
▸ L3MBTL1 Q9Y468 2/20 0.62
▸ MAPT P10636 1/20 0.62
▸ NFKB1 P19838 1/20 0.62
▸ NFKB2 Q00653 1/20 0.62
▸ RELA Q04206 1/20 0.62
▸ CASP3 P42574 1/20 0.54
▸ SENP8 Q96LD8 1/20 0.54
▸ SENP7 Q9BQF6 1/20 0.54
▸ SENP6 Q9GZR1 1/20 0.54
▸ TUBB4A P04350 1/20 0.52
▸ TUBB P07437 1/20 0.52
▸ TUBA3C P0DPH7 1/20 0.52
▸ TUBA1B P68363 1/20 0.52
▸ TUBA4A P68366 1/20 0.52
▸ TUBB4B P68371 1/20 0.52
▸ TUBB3 Q13509 1/20 0.52
▸ TUBB2A Q13885 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30798551 1.00 SMN1; SMN2 (0.62) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT
SCHEMBL29450481 0.83 TUBB4A (0.54) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT
SCHEMBL424747 0.83 TUBB4A (0.54) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT
SCHEMBL403869 0.82 GABRP (0.46) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT
SCHEMBL609984 0.82 KDM4E (0.54) NPC1RAB9AMAPTCASP3SENP8
SCHEMBL14686821 0.81 NPC1 (0.54) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT
SCHEMBL29416399 0.81 TUBB4A (0.52) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT
SCHEMBL4770167 0.81 GABRP (0.65) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT
SCHEMBL3051920 0.81 TUBB4A (0.52) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT
SCHEMBL2527363 0.81 TUBB4A (0.52) SMN1; SMN2NPC1RAB9AL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600716-B2 Compounds for modulating activity of FXR and uses thereof GANNEX PHARMA CO. LTD. (CN) 2026-04-14 — — US disclosed
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF BRISTOL MYERS SQUIBB CO (US) 2026-03-19 — — US disclosed
EP-4073070-B1 COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF GANNEX PHARMA CO LTD (CN) 2026-02-18 — — EP disclosed
EP-4688771-A1 NOVEL FAK DEGRADER COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2026-02-11 — — EP disclosed
US-20260015349-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LTD (CN) 2026-01-15 — — US disclosed
WO-2025245178-A1 PAK4, CSTF2, OR CSTF2T PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS INNOVO THERAPEUTICS, INC. (US) 2025-11-27 — — WO disclosed
US-12448368-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2025-10-21 — — US disclosed
EP-3952870-B1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NANJING ZENSHINE PHARMACEUTICALS CO LTD (CN) 2025-09-24 — — EP disclosed
US-20250215016-A1 ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE Shanghai SIMR Biotechnology Co., Ltd (CN) 2025-07-03 — — US disclosed
WO-2025110699-A1 NOVEL COMPOUND AND USE THEREOF 주식회사 프로티어바이오텍 2025-05-30 — — WO disclosed
EP-2278969-A2 INHIBITORS OF JANUS KINASES Merck Sharp & Dohme Corp. (US) 2011-02-02 — — EP disclosed
US-20100256097-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2010-10-07 — — US disclosed
US-20100256097-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2010-10-07 — — US disclosed
US-20100256097-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2010-10-07 — — US disclosed
EP-2166846-A1 INHIBITORS OF JANUS KINASES Merck Sharp & Dohme Corp. (US) 2010-03-31 — — EP disclosed
WO-2010011375-A2 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2010-01-28 — — WO disclosed
WO-2010011375-A2 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2010-01-28 — — WO disclosed
WO-2008156726-A1 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2008-12-24 — — WO disclosed
WO-2008156726-A1 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2008-12-24 — — WO disclosed
US-20080015183-A1 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2008-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015349-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF CBR1, HCCS, NCOR1 SMN1; SMN2 4261/4885NPC1 953/4885RAB9A 3270/4885
US-12600716-B2 Compounds for modulating activity of FXR and uses thereof FXR1, NR1H4, FXR2 SMN1; SMN2 4261/4885NPC1 42/4885RAB9A 1030/4885
US-20080015183-A1 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES PIGS, HRH4, GPR88 SMN1; SMN2 2871/4885NPC1 1987/4885RAB9A 923/4885
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF CTTN, SRC, PTK2 SMN1; SMN2 1554/4885NPC1 2916/4885RAB9A 178/4885
US-20100256097-A1 INHIBITORS OF JANUS KINASES JAK2, JAK3, JAK1 SMN1; SMN2 3716/4885NPC1 3197/4885RAB9A 2622/4885
US-20250215016-A1 ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE GABRA5, GABRA1, CYP3A5 SMN1; SMN2 2896/4885NPC1 1564/4885RAB9A 1654/4885
US-12448368-B2 Indole compounds as androgen receptor modulators AR, FSHR, ADRB3 SMN1; SMN2 1509/4885NPC1 371/4885RAB9A 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.